BioTuesdays
Vital Therapies

Vital outlines plans for new Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has outlined plans for a possible new Phase 3 clinical trial designed to confirm ELAD’s safety and efficacy in alcohol-induced liver decompensation (AILD), including severe acute alcoholic...

novadaq

Novadaq unveils SPY-Q Case Manager software

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has unveiled its SPY-Q Case Manager (SPY-QCM) software at the Symposium on Advanced Wound Care Fall 2015 meeting in Las Vegas. SPY-QCM is an image acquisition and analysis...

Conatus

HCW starts Conatus Pharma at buy

H.C. Wainwright has initiated coverage of Conatus Pharmaceuticals (NASDAQ:CNAT) with a “buy” rating and $15 price target, saying that the company’s emricasan drug candidate has disease-modifying potential across the...

Can-Fite

Can-Fite in $9-million registered direct offering

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has entered into definitive agreements with institutional investors to raise $9-million through the sale of 2,068,966 American Depository Shares (ADS) at a price of $4.35...

Dipexium Pharmaceuticals

Dipexium presents Locilex data at ICAAC/ICC

Dipexium Pharmaceuticals and research collaborators, JMI Laboratories, have presented new Locilex microbiology data at the American Society for Microbiology’s Interscience Conference of Antimicrobial Agents and...

Cesca Therapeutics Logo

HCW upgrades Cesca Therapeutics to buy

H.C. Wainwright has upgraded Cesca Therapeutics (NASDAQ:KOOL) to “buy” from “neutral” with a new 12-month target price of $2 based on a discounted earnings/revenues analysis. The stock closed at 67 cents on Friday...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.